$ARTL News

Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain

Artelo Bioscience To Present Data On ART26.12 Program At IASP 2026 World Congress On Pain, October 26–30; Growing Body Of Data Supports ART26.12’s Potential As A Novel, Non-Opioid Treatment For Pain Ahead Of Planned Multiple Ascending Dose Study

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Artelo Biosciences Files Provisional Patent Application For ART27.13 As Monotherapy And In Combination With GLP-1 Receptor Agonists

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Artelo Biosciences Announces Reverse Stock Split

Artelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Artelo Biosciences Issued Notification Of Allowance From Japanese Patent Office With Decision To Grant Patent Application For Commercial Formulation Of ART27.13

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY

Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

Artelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical Pharmacology

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions